Mira Dx Names Martin Verhoef, President and Chief Executive Officer

NEW HAVEN, CT - December 7, 2010 – MiraDx today announced that Martin L. Verhoef has been appointed President and Chief Executive Officer effective immediately. Mr. Verhoef has also been appointed to the Company’s Board of Directors.

"We are delighted to have Martin join Mira Dx. His experience and leadership will be of great value during this exciting time in the Company’s evolution, as we have launched our first product and prepare to further broaden the Company‟s capabilities and product offerings. With his recent experience of building world class teams and preparing companies for launch and rapid commercialization Martin brings valuable skills and expertise to Mira Dx,” commented Drs. Joanne Weidhaas and Frank Slack, founders of Mira Dx.

Mr. Verhoef joined Mira Dx in December 2010 from his prior position as President and CEO of PrimeraDx, an emerging Molecular Diagnostics company. In his three years at PrimeraDx Mr. Verhoef successfully developed and built a novel platform for quantitative multiplexed analysis of nucleic acids, put in place an experienced team and raised substantial funds. Prior to PrimeraDx he was President of Ciphergen Biosystems, now known as Vermillion. Mr. Verhoef has also held various management positions at Hewlett-Packard/Agilent in their Life Sciences and Genomics programs. Mr. Verhoef holds a BS degree in Chemistry from the van ‘t Hoff Institute in Rotterdam, The Netherlands.

"When I learned of Mira Dx’s microRNA technology platform I immediately recognized the importance of it in personalized medicine. The research on the mechanisms of microRNA gene interactions and clinical utility thereof is both unique and essential to better understand cancer genetics and help to personalize patient management,” commented Mr. Verhoef. “I am excited to join the company and look forward to building it into a meaningful contribution for improved disease management and healthcare,” Mr Verhoef continued.

About Mira Dx

Mira Dx is a genomics company founded on research discovered at Yale University that is dedicated to the development and commercialization of novel microRNA-based tests for risk assessment and companion diagnostics. Our goal is to provide information that can help clinicians better understand cancer to better serve their patients, allowing earlier diagnosis, better management and ultimately higher cure rates. For more information, please visit www.MiraDx.com.

# # #

For more information, contact:
Stephen Miller, President, MiraDx
smiller@miradx.com, 203-789-9000 x206